JPRN-jRCT2080223696已完成3 期
A Phase 3, Open-label, Randomized Study of Nivolumab Combined with Ipilimumab, or with Standard of Care Chemotherapy, versus Standard of Care Chemotherapy in Participants with Previously Untreated Unresectable or Metastatic Urothelial Cancer(ONO-4538-56/CA209901)
ONO PHARMACEUTICAL CO.,LTD.0 个研究点目标入组 1,290 人开始时间: 2017年10月31日最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 1,290
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 ot applicable（—）
- 性别
- All
入选标准
- •1. Metastatic or inoperable urothelial cancer
- •2. Must have at least 1 lesion with measurable disease
- •3. No prior systemic chemotherapy treatment in the metastatic setting
排除标准
- •1. Patients with active brain metastases or leptomeningeal metastases
- •2. Patients with active, known or suspected autoimmune disease
- •3. Prior treatment with an anti-PD1, anti-PDL1, anti-PDL2, anti-CD137, or anti-CTLA4 antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways
研究者
相似试验
进行中（未招募）
1 期
Study of Nivolumab in Combination With Ipilimumab or with Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy in Treatment of Patients with Untreated Inoperable or Metastatic Urothelial CancerEUCTR2016-003881-14-DEBristol-Myers Squibb International Corporation1,792
进行中（未招募）
1 期
Study of Nivolumab in Combination With Ipilimumab or with Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy in Treatment of Patients with Untreated Inoperable or Metastatic Urothelial CancerEUCTR2016-003881-14-GRBristol-Myers Squibb International Corporation1,792
进行中（未招募）
1 期
Study of Nivolumab in Combination With Ipilimumab or with Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy in Treatment of Patients with Untreated Inoperable or Metastatic Urothelial Cancerntreated Unresectable or Metastatic Urothelial CancerMedDRA version: 20.0Level: LLTClassification code 10064467Term: Urothelial carcinomaSystem Organ Class: 100000004864EUCTR2016-003881-14-NOBristol-Myers Squibb International Corporation1,792
招募中
3 期
A Phase 3, Open-label, Randomized Study of Nivolumab Combined with Ipilimumab, or with Standard of Care Chemotherapy, versus Standard of Care Chemotherapy in participants with Previously Untreated Unresectable or Metastatic Urothelial CancerUrothelial Carcinoma10004994Bladder CancerNL-OMON56458Bristol-Myers Squibb70
进行中（未招募）
1 期
A study of Nivolumab combined with Ipilimumab or Standard of Care chemotherapy, versus standard of care chemotherapy in patients with previously untreated unresectable or metastatic urothelial cancer.ntreated Unresectable or Metastatic Urothelial CancerMedDRA version: 20.0Level: LLTClassification code 10064467Term: Urothelial carcinomaSystem Organ Class: 100000004864EUCTR2016-003881-14-ITBRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATIO1,360